Last 12 months
Inside the activity.
0 purchase rows · 27 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 2,633 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 84,085 F18 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA. F12 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 12,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,268 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") to its partners pursuant to a Rule 10b5-1 trading plan. F17 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 81,452 F15 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F12 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 11,011 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,614 F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners pursuant to a Rule 10b5-1 trading plan. F14 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 79,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 79,074 F11 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F12 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 366,084 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 215,915 F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners pursuant to a Rule 10b5-1 trading plan. F10 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 3,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 622 F7 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("VSF IV") to its partners pursuant to a Rule 10b5-1 trading plan. F8 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and dispositive power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 27,716 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,716 F6 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV IV. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 158,522 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members. F4 · ownership.nature: Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 158,522 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 158,522 F3 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV. F4 · ownership.nature: Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:41 UTC |
Bolzon Bradley J PhDDirector
|
OtherCommon Shares | 615,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026801 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 104,874 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV") to its partners pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and dispositive power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 269 | $156.54 | $42,109.64 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 14 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 158,831 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · shares: These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.26 to $156.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 549 | $156.54 | $85,941.23 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 13 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.26 to $156.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 132 | $155.27 | $20,495.97 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 12 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 159,100 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · shares: These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.23 to $155.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 268 | $155.27 | $41,613.03 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.23 to $155.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 1,119 | $154.57 | $172,958.91 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 159,232 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · shares: These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.00 to $154.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 2,281 | $154.57 | $352,564.13 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.00 to $154.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 2,218 | $153.54 | $340,549.28 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 160,351 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · shares: These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $153.02 to $153.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 4,519 | $153.54 | $693,842.29 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,098 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $153.02 to $153.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 1,540 | $152.38 | $234,659.50 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 162,569 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · shares: These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.00 to $152.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 3,139 | $152.38 | $478,309.21 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,617 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.00 to $152.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 3,144 | $151.49 | $476,299.97 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 164,109 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · shares: These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 6,403 | $151.49 | $970,021.84 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,756 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 1,578 | $150.65 | $237,726.17 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 167,253 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · shares: These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:38 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 3,216 | $150.65 | $484,491.36 |
DisclosureSEC source: 0000899243-21-026800 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,159 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:33 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 25,000 | $156.55 | $3,913,750.00 |
DisclosureSEC source: 0001209191-21-044012 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,007 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:54 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 50 | $130.27 | $6,513.50 |
DisclosureSEC source: 0001209191-21-042811 · doc4.xml · nonDerivative · entry 6 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,007 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:54 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 7,299 | $129.46 | $944,928.54 |
DisclosureSEC source: 0001209191-21-042811 · doc4.xml · nonDerivative · entry 5 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,057 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.20 to $130.11, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:54 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 12,630 | $128.76 | $1,626,238.80 |
DisclosureSEC source: 0001209191-21-042811 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,356 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.195 to $129.195, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:54 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 2,969 | $127.71 | $379,170.99 |
DisclosureSEC source: 0001209191-21-042811 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,986 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.19 to $128.19, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:54 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 881 | $126.62 | $111,552.22 |
DisclosureSEC source: 0001209191-21-042811 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,955 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.175 to $127.175, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:54 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 1,171 | $125.58 | $147,054.18 |
DisclosureSEC source: 0001209191-21-042811 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,836 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.095 to $126.08, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:44 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0001209191-21-041602 · doc4.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,333 Underlying: Common Shares · 30,000 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 15, 2016 with respect to 93,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:44 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
SaleCommon Shares | 3,488 | $127.51 | $444,754.88 |
DisclosureSEC source: 0001209191-21-041602 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,719 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.26 to $127.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:44 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
SaleCommon Shares | 16,129 | $126.86 | $2,046,124.94 |
DisclosureSEC source: 0001209191-21-041602 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,207 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.25 to $127.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:44 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
SaleCommon Shares | 10,383 | $125.39 | $1,301,924.37 |
DisclosureSEC source: 0001209191-21-041602 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.21 to $126.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:44 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 30,000 | $12.57 | $377,100.00 |
DisclosureSEC source: 0001209191-21-041602 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 755 | $129.45 | $97,732.64 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,375 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $129.37 to $129.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 1,100 | $128.65 | $141,516.98 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,130 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.29 to $129.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 800 | $127.88 | $102,307.04 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,230 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $127.29 to $128.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 1,918 | $126.59 | $242,808.44 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,030 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $126.14 to $127.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 5,427 | $125.62 | $681,753.31 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,948 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $125.13 to $126.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:39 UTC |
Treco Douglas ADirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040297 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:23 UTC |
Behbahani AliDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040332 · doc4.xml · derivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:37 UTC |
George SimeonDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040294 · doc4.xml · derivative · entry 1 George Simeon · CIK 0001595117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:39 UTC |
High Katherine ADirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040296 · doc4.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:38 UTC |
Greene JohnDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040295 · doc4.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:36 UTC |
Bolzon Bradley J PhDDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040292 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:35 UTC |
Fleming Harold EdwardDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040291 · doc4.xml · derivative · entry 1 Fleming Harold Edward · CIK 0001857250 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 25,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:34 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 779 | $115.80 | $90,208.20 |
DisclosureSEC source: 0001209191-21-037801 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,719 F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On June 1, 2021, 1,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.